Uncategorized

Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns

Published

on

Aardvark Therapeutics’ obesity asset is based on its lead molecule, which in February was linked to reversible heart safety signals in a healthy volunteer study.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version